{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:33:15Z","timestamp":1793460795277,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41409-021-01476-7","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:17:08Z","timestamp":1634149028000},"page":"160-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60"],"prefix":"10.1038","volume":"57","author":[{"given":"Daniel A.","family":"Pollyea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-3465","authenticated-orcid":false,"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rabinovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1470-0716","authenticated-orcid":false,"given":"Jonathan A.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"1476_CR1","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481\u20135. https:\/\/doi.org\/10.1182\/blood-2005-09-3724. e-pub ahead of print 2006\/02\/04.","journal-title":"Blood"},{"key":"1476_CR2","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/cncr.28129","volume":"119","author":"MS Thein","year":"2013","unstructured":"Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. Cancer. 2013;119:2720\u20137. https:\/\/doi.org\/10.1002\/cncr.28129. e-pub ahead of print 2013\/05\/02.","journal-title":"Cancer"},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B Lowenberg","year":"2009","unstructured":"Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235\u201348. https:\/\/doi.org\/10.1056\/NEJMoa0901409. e-pub ahead of print 2009\/09\/25.","journal-title":"N Engl J Med"},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","volume":"2","author":"S Vasu","year":"2018","unstructured":"Vasu S, Kohlschmidt J, Mrozek K, Eisfeld AK, Nicolet D, Sterling LJ, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2:1645\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2017015222. e-pub ahead of print 2018\/07\/12.","journal-title":"Blood Adv"},{"key":"1476_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Disco. 2014;4:362\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0609. e-pub ahead of print 2013\/12\/19.","journal-title":"Cancer Disco"},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013. e-pub ahead of print 2013\/01\/22.","journal-title":"Cell Stem Cell"},{"key":"1476_CR7","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, Winters A, Pei SS, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859\u2013+. https:\/\/doi.org\/10.1038\/s41591-018-0233-1.","journal-title":"Nat Med"},{"key":"1476_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","volume":"34","author":"CL Jones","year":"2018","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724\u201340. https:\/\/doi.org\/10.1016\/j.ccell.2018.10.005. e-pub ahead of print 2018\/11\/14.","journal-title":"Cancer Cell"},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3:2911\u201319. 0.1182\/bloodadvances.2019000243.","journal-title":"Blood Adv"},{"key":"1476_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971. e-pub ahead of print 2020\/08\/14.","journal-title":"N Engl J Med"},{"key":"1476_CR11","doi-asserted-by":"publisher","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2020. e-pub ahead of print 2020\/10\/30; https:\/\/doi.org\/10.1002\/ajh.26039.","DOI":"10.1002\/ajh.26039"},{"key":"1476_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752. e-pub ahead of print 2018\/10\/27.","journal-title":"Blood"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(18)30010-X. e-pub ahead of print 2018\/01\/18.","journal-title":"Lancet Oncol"},{"key":"1476_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Disco. 2020;10:536\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710. e-pub ahead of print 2020\/01\/25.","journal-title":"Cancer Disco"},{"key":"1476_CR15","doi-asserted-by":"publisher","unstructured":"Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, et al. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am J Hematol. 2020. e-pub ahead of print 2020\/07\/07; https:\/\/doi.org\/10.1002\/ajh.25929.","DOI":"10.1002\/ajh.25929"},{"key":"1476_CR16","doi-asserted-by":"publisher","unstructured":"Arslan S, Zhang J, Dhakal P, Moran J, Naidoo N, Lombardi J, et al. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. Am J Hematol. 2020. e-pub ahead of print 2020\/11\/24; https:\/\/doi.org\/10.1002\/ajh.26057.","DOI":"10.1002\/ajh.26057"},{"key":"1476_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988. e-pub ahead of print 2020\/01\/15.","journal-title":"Blood"},{"key":"1476_CR18","doi-asserted-by":"publisher","unstructured":"Tiong IS, Dillon R, Ivey A, Teh TC, Nguyen P, Cummings N, et al. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2020. e-pub ahead of print 2020\/05\/28; https:\/\/doi.org\/10.1111\/bjh.16722.","DOI":"10.1111\/bjh.16722"},{"key":"1476_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196. e-pub ahead of print 2016\/11\/30.","journal-title":"Blood"},{"key":"1476_CR20","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/jnci\/88.20.1483","volume":"88","author":"EL Sievers","year":"1996","unstructured":"Sievers EL, Lange BJ, Buckley JD, Smith FO, Wells DA, DaigneaultCreech CA, et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. Jnci-J Natl Cancer I. 1996;88:1483\u20138. https:\/\/doi.org\/10.1093\/jnci\/88.20.1483.","journal-title":"Jnci-J Natl Cancer I"},{"key":"1476_CR21","first-page":"101","volume-title":"Minimal Residual Disease Testing, Current Innovations and Future Directions","author":"MRB Loken","year":"2019","unstructured":"Loken MRB, L E, Wells DA. Monitoring AML Response Using \u201cDifference from Normal\u201d Flow Cytometry. In: Druley TE, (ed). Minimal Residual Disease Testing, Current Innovations and Future Directions. Cham, Switzerland: Springer International Publishing AG; 2019. pp. 101\u201337."},{"key":"1476_CR22","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138. e-pub ahead of print 1995\/06\/01.","journal-title":"Bone Marrow Transpl"},{"key":"1476_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004. e-pub ahead of print 2005\/12\/13.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1476_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","volume":"3","author":"ML Sorror","year":"2017","unstructured":"Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, et al. Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol. 2017;3:1675\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2714. e-pub ahead of print 2017\/09\/08.","journal-title":"JAMA Oncol"},{"key":"1476_CR25","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaoncol.2019.0902","volume":"5","author":"ML Sorror","year":"2019","unstructured":"Sorror ML, Storer BE, Nyland J, Estey EH. Revised acute myeloid leukemia composite model using the 2017 European leukemianet risk classification. JAMA Oncol. 2019;5:1062\u20134. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0902. e-pub ahead of print 2019\/05\/17.","journal-title":"JAMA Oncol"},{"key":"1476_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","volume":"21","author":"ML Sorror","year":"2015","unstructured":"Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21:1479\u201387. https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.004. e-pub ahead of print 2015\/04\/12.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1476_CR27","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/bmt.2016.186","volume":"51","author":"JA Gutman","year":"2016","unstructured":"Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, et al. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transpl. 2016;51:1588\u201393. https:\/\/doi.org\/10.1038\/bmt.2016.186. e-pub ahead of print 2016\/07\/12.","journal-title":"Bone Marrow Transpl"},{"key":"1476_CR28","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/bloodadvances.2020001554","volume":"4","author":"P Sharma","year":"2020","unstructured":"Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, et al. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020;4:2227\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2020001554. e-pub ahead of print 2020\/05\/23.","journal-title":"Blood Adv"},{"key":"1476_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1158\/1078-0432.CCR-06-1210","volume":"13","author":"HT Kim","year":"2007","unstructured":"Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13:559\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1210. e-pub ahead of print 2007\/01\/27.","journal-title":"Clin Cancer Res"},{"key":"1476_CR30","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/j.bbmt.2020.08.027","volume":"26","author":"KS Sandhu","year":"2020","unstructured":"Sandhu KS, Dadwal S, Yang D, Mei M, Palmer J, Salhotra A, et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transpl. 2020;26:e322\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.027. e-pub ahead of print 2020\/09\/01.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1476_CR31","doi-asserted-by":"publisher","unstructured":"Zappasodi P, Brociner M, Merati G, Nizzoli ME, Roncoroni E, Boveri E, et al. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed\/refractory acute myeloid leukemia patients. Ann. Hematol. 2020. e-pub ahead of print 2020\/11\/12; https:\/\/doi.org\/10.1007\/s00277-020-04333-7.","DOI":"10.1007\/s00277-020-04333-7"},{"key":"1476_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/blood-2019-127251","volume":"134","author":"K Pratz","year":"2019","unstructured":"Pratz K, CD D, ML A, AG L, M T, VA P, et al. Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax based therapies. Blood. 2019;134:264.","journal-title":"Blood"},{"key":"1476_CR33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"D Salvatore","year":"2018","unstructured":"Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the acute leukemia working party of the European society for blood and marrow transplantation. Haematologica. 2018;103:1317\u201328. https:\/\/doi.org\/10.3324\/haematol.2018.189258. e-pub ahead of print 2018\/05\/12.","journal-title":"Haematologica"},{"key":"1476_CR34","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1602074","volume":"375","author":"F Milano","year":"2016","unstructured":"Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1602074. e-pub ahead of print 2016\/09\/08.","journal-title":"N Engl J Med"},{"key":"1476_CR35","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","volume":"2","author":"M Eapen","year":"2018","unstructured":"Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2:2095\u2013103. https:\/\/doi.org\/10.1182\/bloodadvances.2018021980. e-pub ahead of print 2018\/08\/24.","journal-title":"Blood Adv"},{"key":"1476_CR36","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361. https:\/\/doi.org\/10.1200\/JCO.2016.70.7091. e-pub ahead of print 2017\/04\/06.","journal-title":"J Clin Oncol"},{"key":"1476_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2015-10-677021","volume":"127","author":"TN Wong","year":"2016","unstructured":"Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood. 2016;127:893\u20137. https:\/\/doi.org\/10.1182\/blood-2015-10-677021. e-pub ahead of print 2015\/12\/04.","journal-title":"Blood"},{"key":"1476_CR38","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3109\/10428194.2015.1086918","volume":"57","author":"JK Lamba","year":"2016","unstructured":"Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, et al. Clinical significance of in vivo cytarabine-induced gene expression signature in AML. Leuk Lymphoma. 2016;57:909\u201320. https:\/\/doi.org\/10.3109\/10428194.2015.1086918. e-pub ahead of print 2015\/09\/15.","journal-title":"Leuk Lymphoma"},{"key":"1476_CR39","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","volume":"128","author":"TC Ho","year":"2016","unstructured":"Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O\u2019Dwyer KM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128:1671\u20138. https:\/\/doi.org\/10.1182\/blood-2016-02-695312. e-pub ahead of print 2016\/07\/17.","journal-title":"Blood"},{"key":"1476_CR40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383. https:\/\/doi.org\/10.1200\/JCO.19.03011. e-pub ahead of print 2019\/12\/21.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01476-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01476-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01476-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T19:04:02Z","timestamp":1644260642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01476-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01476-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"assertion":[{"value":"6 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.P. has received research funding and served as a consultant to Abbvie.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}